Global Smart Insulin Pens Market

Smart Insulin Pens Market Size, Share, Growth Analysis, By Product(Smart insulin pen, adaptors for conventional pen), By Connectivity type (Bluetooth, and USB), By Indication(Type 1 diabetes, type 2 diabetes), By End-user(Hospitals & clinics, ambulatory surgical centers, home care settings), By Region(North America, Europe, Asia-Pacific, Latin America), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35A2194 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 143 | Figures: 77

Smart Insulin Pens Market Competitive Landscape

The global smart insulin pens market is highly competitive and somewhat fragmented in nature. To maintain a competitive edge, major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D.

Smart Insulin Pens Market Top Player's Company Profiles  

  • Emperra GmbH
  • Novo Nordisk A/S
  • Medtronic plc
  • Eli Lilly and Company

  • Sanofi S.A.

  • Companion Medical Inc.

  • Diabnext

  • Insulet Corporation

  • Pendiq GmbH

  • Digital Medics Pty Ltd.

  • F. Hoffmann-La Roche AG

  • Ypsomed AG

  • Common Sensing Inc.

  • InjexUK Ltd.

  • Diamesco Co., Ltd.

  • Nipro Corporation

  • Jiangsu Delfu Co., Ltd.

  • Wockhardt Ltd.

  • Biocon Ltd.

Smart Insulin Pens Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Smart Insulin Pens Market size was valued at USD 3.66 billion in 2022 and is expected to rise from USD 4.03 billion in 2023 to reach a value of USD 8.63 billion by 2031, at a CAGR of 10% during the forecast period (2024–2031).

The smart insulin pens market is highly competitive and somewhat fragmented in nature. To maintain a competitive edge, major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Emperra GmbH', 'Novo Nordisk A/S', 'Medtronic plc', 'Eli Lilly and Company', ' Sanofi S.A. ', ' Companion Medical Inc. ', ' Diabnext ', ' Insulet Corporation ', ' Pendiq GmbH ', ' Digital Medics Pty Ltd. ', ' F. Hoffmann-La Roche AG ', ' Ypsomed AG ', ' Common Sensing Inc. ', ' InjexUK Ltd. ', ' Diamesco Co., Ltd. ', ' Nipro Corporation ', ' Jiangsu Delfu Co., Ltd. ', ' Wockhardt Ltd. ', ' Biocon Ltd. '

The population of diabetic patients have increased due to the rapidly evolving society and the growing workload on the younger generation. As a result, insulin products are selling quickly on the market. In recent years, smart insulin pens have become a popular device. On account of people's increasing workloads and busy lifestyles, keeping track of diabetes readings and insulin dose schedules is becoming more and more impossible. As a result, smart technology enters the picture to alleviate these difficulties. The rising incidences of needle stick injuries have boosted sales of smart insulin pens. Owing to this, smart insulin pens market manufacturers are widely producing the product globally, in order to attract high revenues in the next few years.

Increasing latest advancements in research & development activities in the healthcare department, coupled with the increase in diabetic patients worldwide are the key industry trends for the smart insulin pens market. Additionally, increase in new innovative products by market manufacturers to cater to the need of smart insulin pens are also projected to create lucrative growth opportunities for this market in the long run.

Demographically, the smart insulin pens market is widespread into the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Among these, every region is further classified based on the key countries contributing to the market growth. The rise in prevalence of diabetes in countries such as Canada and the US augments the cost of smart insulin pumps in North America, thus, helping it contribute the largest share in 2021 and to continue so in the forecast period. In addition to this, the presence of multiple players in this region, coupled with the high rate of technological adoption is also driving the North America smart insulin pens market. Furthermore, the market in North America is expected to be driven by new product launches and related FDA approvals.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Insulin Pens Market
Buy Now GET FREE SAMPLE
Insulin Storage Devices Market
Buy Now GET FREE SAMPLE
Diabetes Care Devices Market
Buy Now GET FREE SAMPLE
Diabetes Device Market
Buy Now GET FREE SAMPLE
Human Insulin Market
Buy Now GET FREE SAMPLE
Insulin Pump Market
Buy Now GET FREE SAMPLE
Diabetes Care Devices and Drugs Market
Buy Now GET FREE SAMPLE
Pen Needles Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Smart Insulin Pens Market

Report ID: SQMIG35A2194

$5,300
BUY NOW GET FREE SAMPLE